Patient-derived Xenograft Models to Improve Targeted Therapy in Epithelial Ovarian Cancer Treatment
Open accessAbstract
Despite increasing evidence that precision therapy targeted to the molecular drivers of a cancer has the potential to improve clinical outcomes, high-grade epithelial ovarian cancer (OC) patients are currently treated without consideration of molecular phenotype, and predictive biomarkers that could better inform treatment remain unknown. Delivery of precision therapy requires improved integration of laboratory-based models and cutting-edge clinical research, with pre-clinical models predicting patient subsets that will benefit from a particular targeted therapeutic. Patient-derived xenografts (PDXs) are renewable tumor models engrafted in mice, generated from fresh human tumors without prior in vitro exposure. PDX models allow an invaluable assessment of tumor evolution and adaptive response to therapy. PDX models have been applied to pre-clinical drug testing and biomarker identification in a number of cancers including ovarian, pancreatic, breast, and prostate cancers. These models have been shown to be biologically stable and accurately reflect the patient tumor with regards to histopathology, gene expression, genetic mutations, and therapeutic response. However, pre-clinical analyses of molecularly annotated PDX models derived from high-grade serous ovarian cancer (HG-SOC) remain limited. In vivo response to conventional and/or targeted therapeutics has only been described for very small numbers of individual HG-SOC PDX in conjunction with sparse molecular annotation and patient outcome data. Recently, two consecutive panels of epithelial OC PDX correlate in vivo platinum response with molecular aberrations and source patient clinical outcomes. These studies underpin the value of PDX models to better direct chemotherapy and predict response to targeted therapy. Tumor heterogeneity, before and following treatment, as well as the importance of multiple molecular aberrations per individual tumor underscore some of the important issues addressed in PDX models.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
An extensive review of ovarian cancer PDX models by Scott et al. (2013) highlighted a number of gaps in the field related to variations in methodologies, genetic stability over multiple generations, representation of few ovarian cancer histotypes and the limitation of using immunocompromised mice as hosts.
“An extensive review of ovarian cancer PDX models by Scott et al. (2013), highlighted a number of gaps in the field related to variations in methodologies, genetic stability over multiple generations, representation of few ovarian cancer histotypes and the limitation of using immunocompromised mice as hosts.”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Scott et al. (2013)
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Engin Üstün, Y. (n.d.) · DergiPark (Istanbul University) · Cited by 170,090 · see citing works
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927 · see citing works
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · see citing works
Rubin, M., & Stephen, C. D. (1993) · Cited by 3,149 · see citing works
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279 · see citing works
The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory
Kurman, R. J., & Shih, I. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181cf3d79 · Cited by 1,850 · see citing works
Cancer Research Communications
Calura, E., Fruscio, R., Paracchini, L., Bignotti, E., Martini, P., Sales, G., Beltrame, L., Clivio, L., Ceppi, L., Di Marino, M., et al. (2021) · doi:10.1158/1078-0432 · Cited by 1,537 · see citing works
Evaluating cell lines as tumour models by comparison of genomic profiles
Domcke, S., Sinha, R., Levine, D. A., Sander, C., & Schultz, N. D. (2013) · Nature Communications · doi:10.1038/ncomms3126 · Cited by 1,426 · see citing works
Patient-derived tumour xenografts as models for oncology drug development
Tentler, J. J., Tan, A. C., Weekes, C. D., Jimeno, A., Leong, S., Pitts, T. M., Arcaroli, J. J., Messersmith, W. A., & Eckhardt, S. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.61 · Cited by 1,277 · see citing works
Medeiros, F., Muto, M. G., Lee, Y., Elvin, J. A., Callahan, M. J., Feltmate, C. M., Garber, J. E., Cramer, D. W., & Crum, C. P. (2006) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000180854.28831.77 · Cited by 913 · see citing works
The Mammalian Ovary from Genesis to Revelation
Edson, M. A., Nagaraja, A. K., & Matzuk, M. M. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0012 · Cited by 828 · see citing works
Piek, J. M. J., van Diest, P. J., Zweemer, R. P., Jansen, J. W., Poort-Keesom, R. J. J., Menko, F. H., Gille, J. J. P., Jongsma, A. P. M., Pals, G., Kenemans, P., et al. (2001) · The Journal of Pathology · doi:10.1002/path.1000 · Cited by 785 · see citing works
Cho, K. R., & Shih, I. (2008) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092246 · Cited by 694 · see citing works
Development of a Syngeneic Mouse Model for Events Related to Ovarian Cancer
Roby, K. F., Taylor, C. C., Sweetwood, J. P., Cheng, Y., Pace, J. L., Tawfik, O., Persons, D. L., Smith, P. G., & Terranova, P. F. (2000) · Carcinogenesis · doi:10.1093/carcin/21.4.585 · Cited by 593 · see citing works
The distal fallopian tube: a new model for pelvic serous carcinogenesis
Crum, C. P., Drapkin, R., Miron, A., Ince, T. A., Muto, M. G., Kindelberger, D. W., & Lee, Y. (2007) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e328011a21f · Cited by 513 · see citing works
Establishment of human tumor xenografts in immunodeficient mice
Morton, C. L., & Houghton, P. J. (2007) · Nature Protocols · doi:10.1038/nprot.2007.25 · Cited by 489 · see citing works
A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays
Marangoni, E., Vincent‐Salomon, A., Auger, N., Degeorges, A., Assayag, F., de Crémoux, P., de Plater, L., Guyader, C., Pinieux, G. D. B. D., Judde, J., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0078 · Cited by 423 · see citing works
An In vivo Platform for Translational Drug Development in Pancreatic Cancer
Rubio‐Viqueira, B., Jimeno, A., Cusatis, G., Zhang, X., Iacobuzio–Donahue, C. A., Karikari, C. A., Shi, C., Danenberg, K. D., Danenberg, P. V., Kuramochi, H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0113 · Cited by 414 · see citing works
Idrissou, M., Boisnier, T., Sánchez, A., Khoufaf, F. Z. H., Penault-Llorca, F. M., Bignon, Y., & Bernard-Gallon, D. J. (2018) · Cancer Genomics & Proteomics · doi:10.21873/cgp · Cited by 372 · see citing works
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
Press, J. Z., Luca, A. D., Boyd, N., Young, S. S., Troussard, A. A., Ridge, Y., Kaurah, P., Kalloger, S. E., Blood, K. A., Smith, M. J., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-17 · Cited by 287 · see citing works
Fichtner, I., Rolff, J., Soong, R., Hoffmann, J., Hammer, S., Sommer, A., Becker, M., & Merk, J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0138 · Cited by 286 · see citing works
The Hedgehog Signaling Pathway in Cancer
Evangelista, M., Tian, H., & de Sauvage, F. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1736 · Cited by 247 · see citing works
Bowen, N. J., Walker, L. D., Matyunina, L. V., Logani, S., Totten, K. A., Benigno, B. B., & McDonald, J. F. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-71 · Cited by 239 · see citing works
Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells
Stewart, J. M., Shaw, P. A., Gedye, C. A., Bernardini, M. Q., Neel, B. G., & Ailles, L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005529108 · Cited by 210 · see citing works
Fallopian Tube Carcinoma: A Review
Pectasides, D. G., Pectasides, E., & Economopoulos, T. (2006) · The Oncologist · doi:10.1634/theoncologist.11-8-902 · Cited by 182 · see citing works
Yoshida, T., Kinoshita, H., Segawa, T., Nakamura, E., Inoue, T., Shimizu, Y., Kamoto, T., & Ogawa, O. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0817 · Cited by 178 · see citing works
Stordal, B., Timms, K. M., Farrelly, A. M., Gallagher, D., Busschots, S., Renaud, M., Thery, J., Williams, D., Potter, J., Tran, T., et al. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2012.12.007 · Cited by 157 · see citing works
Molecular Pathways: The Hedgehog Signaling Pathway in Cancer
McMillan, R. H., & Matsui, W. H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2509 · Cited by 157 · see citing works
BRCA1/2-related ovarian cancers are of tubal origin: a hypothesis
Piek, J. M. J., Verheijen, R. H. M., Kenemans, P., Massuger, L. F. A. G., Bulten, H., & van Diest, P. J. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(03)00365-2 · Cited by 147 · see citing works
Integrated genomic analyses of ovarian carcinoma
The Cancer Genome Atlas Research Network (2011) · Nature · doi:10.1038/nature10166 · Cited by 129 · see citing works
Role of Hedgehog Signaling in Ovarian Cancer
Bhattacharya, R., Kwon, J., Ali, B., Wang, E., Patra, S., Shridhar, V., & Mukherjee, P. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1414 · Cited by 124 · see citing works
Bankert, R. B., Balu‐Iyer, S. V., Odunsi, K. O., Shultz, L. D., Kelleher, R. J., Barnas, J. L., Simpson-Abelson, M. R., Parsons, R., & Yokota, S. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024420 · Cited by 115 · see citing works
STICS SCOUTs and p53 signatures a new language for pelvic serous carcinogenesis
Crum, C. P. (2010) · Frontiers in Bioscience-Elite · doi:10.2741/e275 · Cited by 106 · see citing works
Lee, C., Xue, H., Sutcliffe, M., Gout, P. W., Huntsman, D. D., Miller, D. M., Gilks, C. B., & Wang, Y. Z. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.09.025 · Cited by 101 · see citing works
Pentheroudakis, G. E., & Pavlidis, N. A. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.10.003 · Cited by 100 · see citing works
Vidal, A., Muñoz, C., Guillén, M.-J., Moretó, J., Puertas, S., Martínez‐Iniesta, M., Figueras, A., Padullés, L., García-Rodríguez, F. J., Berdiel‐Acer, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1513 · Cited by 99 · see citing works
Ghamande, S. A., Hylander, B. L., Oflazoglu, E., Lele, S., Fanslow, W. C., & Repasky, E. A. (2001) · PubMed · Cited by 95 · see citing works
Simpson-Abelson, M. R., Sonnenberg, G. F., Takita, H., Yokota, S. J., Conway, T. F., Kelleher, R. J., Shultz, L. D., Barcos, M. P., & Bankert, R. B. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.10.7009 · Cited by 94 · see citing works
Human–SCID mouse chimeric models for the evaluation of anti-cancer therapies
Bankert, R. B., Egilmez, N. K., & Hess, S. D. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)01943-3 · Cited by 92 · see citing works
Origin of the vasculature supporting growth of primary patient tumor xenografts
Hylander, B. L., Punt, N., Tang, H., Hillman, J. C., Vaughan, M. M., Bshara, W., Pitoniak, R., & Repasky, E. A. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-110 · Cited by 81 · see citing works
McCann, C. K., Growdon, W. B., Kulkarni-Datar, K. S., Curley, M. D., Friel, A. M., Proctor, J., Sheikh, H., Deyneko, I. V., Ferguson, J. A., Vathipadiekal, V., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028077 · Cited by 80 · see citing works
Nutu, M., Weijdegård, B., Thomas, P., Thurin‐Kjellberg, A., Billig, H., & Larsson, D. G. J. (2009) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-7-89 · Cited by 76 · see citing works
Press, J. Z., Kenyon, J. A., Xue, H., Miller, M. A., Luca, A. D., Miller, D. M., Huntsman, D. D., Gilks, C. B., McAlpine, J. N., & Wang, Y. Z. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.03.011 · Cited by 70 · see citing works
Kortmann, U., McAlpine, J. N., Xue, H., Guan, J., Ha, G., Tully, S., Shafait, S., Lau, A., Cranston, A. N., O’Connor, M. J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1382 · Cited by 70 · see citing works
Merk, J., Rolff, J., Becker, M., Leschber, G., & Fichtner, I. (2009) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2009.03.054 · Cited by 59 · see citing works
Characterization of Human Ovarian Carcinomas in a SCID Mouse Model
Xu, Y., Silver, D. F., Yang, N.-P., Oflazoglu, E., Hempling, R. E., Piver, M. S., & Repasky, E. A. (1999) · Gynecologic Oncology · doi:10.1006/gyno.1998.5238 · Cited by 50 · see citing works
The war on cancer: are we winning?
Duffy, M. J. (2013) · Tumor Biology · doi:10.1007/s13277-013-0759-2 · Cited by 47 · see citing works
de Plater, L., Laugé, A., Guyader, C., Poupon, M. F., Assayag, F., de Crémoux, P., Vincent‐Salomon, A., Stoppa‐Lyonnet, D., Sigal‐Zafrani, B., Fontaine, J.-J., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605900 · Cited by 46 · see citing works
Fiebig, H., Schüler, J. B., Bausch, N., Hofmann, M., Metz, T. M., & Korrat, A. (2007) · PubMed · Cited by 39 · see citing works
Kolfschoten, G. M., Pinedo, H. M., Scheffer, P. G., Schlüper, H. M. M., Erkelens, C. A. M., & Boven, E. (2000) · Gynecologic Oncology · doi:10.1006/gyno.1999.5689 · Cited by 36 · see citing works
A Human Ovarian Carcinoma Murine Xenograft Model Useful for Preclinical Trials
Elkas, J. C., Baldwin, R. L., Pegram, M. D., Tseng, Y., Slamon, D. J., & Karlan, B. Y. (2002) · Gynecologic Oncology · doi:10.1006/gyno.2002.6819 · Cited by 35 · see citing works
Models of ovarian cancer metastasis: Murine models
Šale, S., & Oršulić, S. (2006) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2006.05.006 · Cited by 33 · see citing works
Gillett, W. R., Mitchell, A., & Hurst, P. R. (1991) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a137398 · Cited by 32 · see citing works
Effects of IL-12 on Human Ovarian Tumors Engrafted into SCID Mice
Silver, D. F., Hempling, R. E., Piver, M. S., & Repasky, E. A. (1999) · Gynecologic Oncology · doi:10.1006/gyno.1998.5239 · Cited by 27 · see citing works
Indraccolo, S., Tisato, V., Agata, S., Moserle, L., Ferrari, S., Callegaro, M., Persano, L., Palma, M. D., Scaini, M. C., Esposito, G., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.057 · Cited by 27 · see citing works
Silver, D. F., Hempling, R. E., Piver, M. S., & Repasky, E. A. (2000) · Gynecologic Oncology · doi:10.1006/gyno.2000.5782 · Cited by 26 · see citing works
Ex-vivo fine needle aspiration. A new method of xenografting non-small cell carcinoma of the lung
Mourad, W. A. (1995) · Lung Cancer · doi:10.1016/0169-5002(95)90591-x · Cited by 2 · see citing works
Flagged first, then by citations
1 of the 58 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Hydrogel microenvironments for cancer spheroid growth and drug screening
Li, Y., & Kumacheva, E. (2018) · Science Advances · doi:10.1126/sciadv.aas8998 · Cited by 349 · see citing works
Rosfjord, E. C., Lucas, J., Li, G., & Gerber, H. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.06.008 · Cited by 178 · see citing works
An Integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts
Cho, S., Kang, W., Han, J. Y., Min, S., Kang, J., Lee, A., Kwon, J. Y., Lee, C., & Park, H. (2016) · Molecules and Cells · doi:10.14348/molcells.2016.2350 · Cited by 151 · see citing works
Patient-Derived Xenograft Models of Breast Cancer and Their Application
Murayama, T., & Gotoh, N. (2019) · Cells · doi:10.3390/cells8060621 · Cited by 138 · see citing works
Predictive approaches for drug combination discovery in cancer
Tonekaboni, S. A. M., Ghoraie, L. S., Manem, V. S., & Haibe‐Kains, B. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw104 · Cited by 118 · see citing works
Patient-Derived Tumor Xenografts Are Susceptible to Formation of Human Lymphocytic Tumors
Bondarenko, G. I., Ugolkov, A. V., Rohan, S. M., Kulesza, P., Dubrovskyi, O., Gursel, D. B., Mathews, J. A., O’Halloran, T. V., Wei, J., & Mazar, A. P. (2015) · Neoplasia · doi:10.1016/j.neo.2015.09.004 · Cited by 97 · see citing works
The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
Ordóñez, J. L., Amaral, A. T., Carcaboso, A. M., Herrero‐Martín, D., García-Macías, M. D. C., Sevillano, V., Alonso, D., Pascual‐Pasto, G., San‐Segundo, L., Vilà-Ubach, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4303 · Cited by 95 · see citing works
A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity
Nelson, L., Tighe, A., Golder, A., Littler, S., Bakker, B., Moralli, D., Baker, S. M., Donaldson, I. J., Spierings, D. C. J., Wardenaar, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14551-2 · Cited by 94 · see citing works
Khalifa, A. M., Elsheikh, M. A., Khalifa, A., & Elnaggar, Y. S. R. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.08.034 · Cited by 94 · see citing works
Current Status of Patient-Derived Ovarian Cancer Models
Maru, Y., & Hippo, Y. (2019) · Cells · doi:10.3390/cells8050505 · Cited by 88 · see citing works
Beyond genomics: Critical evaluation of cell line utility for ovarian cancer research
Elias, K. M., Emori, M. M., Papp, E., MacDuffie, E., Konecny, G. E., Velculescu, V. E., & Drapkin, R. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.08.017 · Cited by 82 · see citing works
Alkema, N. G., Wisman, G. B. A., van der Zee, A. G. J., van Vugt, M. A. T. M., & de Jong, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.005 · Cited by 80 · see citing works
Directed Differentiation of Human Induced Pluripotent Stem Cells into Fallopian Tube Epithelium
Yucer, N., Holzapfel, M., Vogel, T. J., Lenaeus, L., Ornelas, L., Laury, A. R., Sareen, D., Barrett, R. J., Karlan, B. Y., & Svendsen, C. N. (2017) · Scientific Reports · doi:10.1038/s41598-017-05519-2 · Cited by 74 · see citing works
Zhu, Y., Tian, T., Li, Z., Tang, Z., Wang, L., Wu, J., Li, Y., Dong, B., Li, Y., Li, N., et al. (2015) · Scientific Reports · doi:10.1038/srep08542 · Cited by 75 · see citing works
Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies
Heo, E. J., Cho, Y., Cho, W. C. S., Hong, J. E., Jeon, H., Oh, D., Choi, Y., Song, S. Y., Choi, J., Bae, D., et al. (2017) · Cancer Research and Treatment · doi:10.4143/crt.2016.322 · Cited by 70 · see citing works
Yee, C., Dickson, K.-A., Muntasir, M. N., Ma, Y., & Marsh, D. J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.836984 · Cited by 66 · see citing works
Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias
Wang, K., Sánchez-Martín, M., Wang, X., Knapp, K. M., Koche, R. P., Vu, L., Nahas, M. K., He, J., Hadler, M., Stein, E. M., et al. (2016) · Leukemia · doi:10.1038/leu.2016.166 · Cited by 67 · see citing works
Establishment of patient-derived cancer xenografts in immunodeficient NOG mice
Chijiwa, T., Kawai, K., NOGUCHI, A., Sato, H., Hayashi, A., Cho, H., Shiozawa, M., Kishida, T., Morinaga, S., Yokose, T., et al. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2997 · Cited by 60 · see citing works
Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived Xenografts
Butler, K. A., Hou, X., Becker, M. A., Zanfagnin, V., Enderica-Gonzalez, S., Visscher, D. W., Kalli, K. R., Tienchaianada, P., Haluska, P., & Weroha, S. J. (2017) · Neoplasia · doi:10.1016/j.neo.2017.04.007 · Cited by 59 · see citing works
Patient-derived xenografts as compatible models for precision oncology
Cho, S. (2020) · Laboratory Animal Research · doi:10.1186/s42826-020-00045-1 · Cited by 58 · see citing works
Loessner, D., Holzapfel, B. M., & Clements, J. A. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.06.001 · Cited by 57 · see citing works
Pépin, D., Sosulski, A., Zhang, L., Wang, D., Vathipadiekal, V., Hendren, K., Coletti, C. M., Yu, A., Castro, C. M., Birrer, M. J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1510604112 · Cited by 54 · see citing works
Alkema, N. G., Tomar, T., Duiker, E. W., Meersma, G. J., Klip, H. G., van der Zee, A. G. J., Wisman, G. B. A., & de Jong, S. (2015) · Scientific Reports · doi:10.1038/srep14495 · Cited by 54 · see citing works
You, B., Freyer, G., González-Martı́n, A., Lheureux, S., McNeish, I. A., Penson, R. T., Pignata, S., & Pujade-Lauraine, É. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102294 · Cited by 53 · see citing works
Cancer mouse models: Past, present and future
Khaled, W. T., & Liu, P. (2014) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2014.04.003 · Cited by 52 · see citing works
Iavarone, C., Zervantonakis, I. K., Selfors, L. M., Palakurthi, S. S., Liu, J. F., Drapkin, R., Matulonis, U. A., Hallberg, D. L., Velculescu, V. E., Leverson, J. D., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0413 · Cited by 51 · see citing works
Dong, R., Qiang, W., Guo, H., Xu, X., Kim, J. J., Mazar, A., Kong, B., & Wei, J.-J. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0318-6 · Cited by 49 · see citing works
Ovarian and cervical cancer patient derived xenografts: The past, present, and future
Boone, J. D., Dobbin, Z. C., Straughn, J. M., & Buchsbaum, D. J. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.05.022 · Cited by 48 · see citing works
Emerging and Evolving Ovarian Cancer Animal Models
Bobbs, A. S., Cole, J. M., & Dahl, K. D. C. (2015) · Cancer Growth and Metastasis · doi:10.4137/cgm.s21221 · Cited by 48 · see citing works
The promise and challenge of ovarian cancer models.
Hasan, N., Öhman, A., & Dinulescu, D. M. (2015) · PubMed · doi:10.3978/j.issn.2218-676x.2015.01.02 · Cited by 46 · see citing works
Ricciardelli, C., Lokman, N. A., Sabit, I., Gunasegaran, K., Bonner, W. M., Pyragius, C. E., Macpherson, A. M., & Oehler, M. K. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.02.006 · Cited by 46 · see citing works
Liu, Y., Chanana, P., Davila, J. I., Hou, X., Zanfagnin, V., McGehee, C. D., Goode, E. L., Polley, E. C., Haluska, P., Weroha, S. J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-42680-2 · Cited by 46 · see citing works
Cavalloni, G., Neia, C. P., Sassi, F. P., Chiorino, G., Sarotto, I., Aglietta, M., & Leone, F. (2016) · BMC Cancer · doi:10.1186/s12885-016-2136-1 · Cited by 43 · see citing works
Bambury, R. M., Benjamin, D. J., Chaim, J. L., Zabor, E. C., Sullivan, J., Garcia-Grossman, I. R., Regazzi, A. M., Ostrovnaya, I., Apollo, A., Xiao, H., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0354 · Cited by 39 · see citing works
Tomar, T., de Jong, S., Alkema, N. G., Hoekman, R. L., Meersma, G. J., Klip, H. G., van der Zee, A. G., & Wisman, G. B. A. (2016) · Genome Medicine · doi:10.1186/s13073-016-0361-5 · Cited by 38 · see citing works
Patient-Derived Xenograft Models in Gynecologic Malignancies
Scott, C. L., MacKay, H. J., & Haluska, P. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.e258 · Cited by 37 · see citing works
Radaelli, E., Hermans, E., Omodho, L., Francis, A., Borght, S. V., Marine, J., van den Oord, J., & Amant, F. C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124974 · Cited by 35 · see citing works
Chirshev, E., Hojo, N., Bertucci, A., Sanderman, L., Nguyen, A. L., Wang, H., Suzuki, T., Brito, E., Martinez, S. R., Castañón, C., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12762 · Cited by 35 · see citing works
Precision or Personalized Medicine for Cancer Chemotherapy: Is there a Role for Herbal Medicine
Wang, Z. K., Liu, X., Ho, R., Lam, C. W. K., & Chow, M. (2016) · Molecules · doi:10.3390/molecules21070889 · Cited by 34 · see citing works
Abreu, S., Silva, F., Mendes, R., Mendes, T. F., Teixeira, M., Santo, V. E., Boghaert, E. R., Félix, A., & Brito, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-76291-z · Cited by 31 · see citing works
Network Modeling Identifies Patient-specific Pathways in Glioblastoma
Tunçbağ, N., Milani, P., Pokorny, J. L., Johnson, H., Sio, T. T.-W., Dalin, S., Iyekegbe, D. O., White, F. M., Sarkaria, J. N., & Fraenkel, E. (2016) · Scientific Reports · doi:10.1038/srep28668 · Cited by 31 · see citing works
Biological basis of cancer health disparities: resources and challenges for research.
Deshmukh, S. K., Azim, S., Ahmad, A., Zubair, H., Tyagi, N., Srivastava, S. K., Bhardwaj, A., Singh, S., Rocconi, R. P., & Singh, A. P. (2017) · PubMed Central · Cited by 31 · see citing works
Zhang, T., Zhang, L., Fan, S., Zhang, M., Fu, H., Liu, Y., Yin, X., Chen, H., Xie, L., Zhang, J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134493 · Cited by 30 · see citing works
Lane, A. N., Higashi, R. M., & Fan, T. W. ‐. (2016) · Metabolomics · doi:10.1007/s11306-016-1065-y · Cited by 30 · see citing works
Cybulska, P., Stewart, J. M., Sayad, A., Virtanen, C., Shaw, P. A., Clarke, B. A., Stickle, N. H., Bernardini, M. Q., & Neel, B. G. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.01.019 · Cited by 30 · see citing works
Steinkamp, M. P., Lagutina, I. V., Brayer, K. J., Schultz, F. A., Burke, D., Pankratz, V. S., Adams, S. F., Hudson, L. G., Ness, S. A., & Wandinger‐Ness, A. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0300 · Cited by 27 · see citing works
Establishment and characterization of cell lines from chromosomal instable colorectal cancer
Maletzki, C. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i1.164 · Cited by 25 · see citing works
Thu, K. L., Papari-Zareei, M., Stastny, V., Song, K., Peyton, M., Martínez, V. D., Zhang, Y.-A., Castro, I. B., Varella‐Garcia, M., Liang, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9929 · Cited by 24 · see citing works
Strategies for Delivery of siRNAs to Ovarian Cancer Cells
Farra, R., Maruna, M., Perrone, F. M., Grassi, M., Benedetti, F. M., Maddaloni, M., Boustani, M. E., Parisi, S., Rizzolio, F., Forte, G., et al. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11100547 · Cited by 23 · see citing works
Cybula, M., Wang, L., Wang, L., Drumond‐Bock, A. L., Moxley, K. M., Benbrook, D. M., Gunderson-Jackson, C., Ruiz-Echevarría, M. J., Bhattacharya, R., Mukherjee, P., et al. (2021) · Cancers · doi:10.3390/cancers13246288 · Cited by 23 · see citing works
Horst, E. N., Bregenzer, M. E., Mehta, P., Snyder, C. S., Repetto, T., Yang‐Hartwich, Y., & Mehta, G. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.04.041 · Cited by 23 · see citing works
Aptamers as potential therapeutic agents for ovarian cancer
Henri, J., MacDonald, J. P., Strom, M., Duan, W., & Shigdar, S. L. (2017) · Biochimie · doi:10.1016/j.biochi.2017.12.001 · Cited by 22 · see citing works
In vitro three‐dimensional culture systems of salivary glands
Tanaka, J., & Mishima, K. (2020) · Pathology International · doi:10.1111/pin.12947 · Cited by 20 · see citing works
Patient-derived xenograft models for oncology drug discovery
Li, G. (2015) · Journal of Cancer Metastasis and Treatment · doi:10.4103/2394-4722.152769 · Cited by 19 · see citing works
Establishment of the PDTX model of gynecological tumors.
Yang, W., Fan, W., Ye, M.-X., Li, Z., Gu, C., Zhu, Y., Hao, Y., Wang, Z.-Q., Wang, L., & Meng, Y. (2019) · Europe PMC (PubMed Central) · Cited by 17 · see citing works
Kleinmanns, K., Bischof, K., Anandan, S., Popa, M. L., Akslen, L. A., Fosse, V., Karlsen, I. T., Gjertsen, B. T., Bjørge, L., & McCormack, E. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102782 · Cited by 17 · see citing works
Wu, J., Zheng, Y., Tian, Q., Yao, M., & Yi, X. (2019) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.14054 · Cited by 16 · see citing works
Huang, Y., Xu, J., Li, K., Wang, J., Dai, Y., & Kang, Y. (2021) · Cancer Management and Research · doi:10.2147/cmar.s276799 · Cited by 13 · see citing works
Instructive Hydrogels for Primary Tumor Cell Culture: Current Status and Outlook
Jia, Y., Wei, Z., Zhang, S., Yang, B., & Li, Y. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202102479 · Cited by 13 · see citing works
Hall, J. C., Marlow, L. A., Mathias, A. C., Dawson, L. K., Durham, W. F., Meshaw, K. A., Mullin, R. J., Synnott, A. J., Small, D. L., Krishna, M., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0875-z · Cited by 14 · see citing works
Shin, S. H., Park, S. S., Ju, E. J., Park, J. H., KO, E. J., Hwang, J. J., Suh, Y., Jang, S. J., Lee, J. S., Ko, B.-K., et al. (2018) · Anticancer Research · doi:10.21873/anticanres.12220 · Cited by 13 · see citing works
Chang, Y., Lin, Y., Huang, C., Harnod, T., & Ding, D. (2022) · PubMed Central · Cited by 11 · see citing works
Stimuli-responsive sugar-derived hydrogels: A modern approach in cancer biology
Maity, S., Chatterjee, A., & Ganguly, J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817592-7.00018-6 · Cited by 11 · see citing works
Mukherjee, S., Sundfeldt, K., Borrebaeck, C. A. K., & Jakobsson, M. E. (2021) · Proteomes · doi:10.3390/proteomes9020025 · Cited by 10 · see citing works
Xenotransplantation Models to Study the Effects of Toxicants on Human Fetal Tissues
Spade, D. J., McDonnell, E. V., Heger, N. E., Sanders, J. A., Saffarini, C. M., Gruppuso, P. A., Paepe, M. E. D., & Boekelheide, K. (2014) · Birth Defects Research Part B Developmental and Reproductive Toxicology · doi:10.1002/bdrb.21131 · Cited by 10 · see citing works
Establishment and preclinical application of a patient-derived xenograft model for uterine cancer
Jeong, S. Y., Cho, Y., Ryu, J., Choi, J., Hwang, J.-R., Kim, B., Lee, Y.-Y., Kim, H. S., & Lee, J. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.04.028 · Cited by 10 · see citing works
Tang, P., Thongrom, B., Arora, S., & Haag, R. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300842 · Cited by 9 · see citing works
Predictive In Vivo Models for Oncology
Behrens, D., Rolff, J., & Hoffmann, J. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_29 · Cited by 9 · see citing works
Chang, Y., Wu, K., Harnod, T., & Ding, D. (2021) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj_63_21 · Cited by 8 · see citing works
Pillai, S. P. S., & Uthamanthil, R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804010-2.00001-1 · Cited by 8 · see citing works
Nikeghbal, P., Zamanian, D., Burke, D., & Steinkamp, M. P. (2025) · BMC Cancer · doi:10.1186/s12885-025-14811-8 · Cited by 8 · see citing works
Jang, S. Y., Bae, H. I., Lee, I. K., Park, H. K., & Cho, C. (2015) · Gut and Liver · doi:10.5009/gnl14279 · Cited by 7 · see citing works
Gill, S. E., Zhang, Q., Keeney, G. L., Cliby, W. A., & Weroha, S. J. (2017) · Oncotarget · doi:10.18632/oncotarget.19620 · Cited by 7 · see citing works
Xenograft Models of Ovarian Cancer for Therapy Evaluation
Popa, M. L., Fosse, V., Kleinmanns, K., Bjørge, L., & McCormack, E. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1956-8_18 · Cited by 7 · see citing works
The Proteolytic Landscape of Ovarian Cancer: Applications in Nanomedicine
O’Connell, C., VandenHeuvel, S. N., Kamat, A. A., Raghavan, S. A., & Godin, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179981 · Cited by 6 · see citing works
IMGN853 Induces Autophagic Cell Death in Combination Therapy for Ovarian Cancer
Chelariu-Raicu, A., Vu, T. C., Umamaheswaran, S., Stur, E., Hanjra, P., Han, Y., Hu, M., Lin, J., Lawson, B. C., Liu, J., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0215 · Cited by 5 · see citing works
Patient-derived xenograft models for the study of benign human neoplasms
de Souza, J. C., Miguita, L., Gomez, R. S., & Gomes, C. C. (2021) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2021.104630 · Cited by 5 · see citing works
Review on Advanced Cancer Modeling for a Cancer Study
Cho, Y. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44110362 · Cited by 4 · see citing works
Three-dimensional in vitro models in head and neck cancer: current trends and applications
Amiri, M., Tabatabai, T. S., Seifi, Z., Rostaminasab, G., Mikaeili, A., Hosseini, F., & Rezakhani, L. (2025) · Medical Oncology · doi:10.1007/s12032-025-02737-x · Cited by 4 · see citing works
A Preliminary Study on the Establishment of the PDTX Model
Liu, Y., Zhu, Y.-P., Cai, M., Ke, B., Li, B., Liu, N., Xue, Q., Zhan, H., Deng, J.-Y., Zhang, L., et al. (2020) · Cancer Management and Research · doi:10.2147/cmar.s230668 · Cited by 3 · see citing works
Application of PDX Cancer Models in Co-clinical Trials and Personalized/Precision Medicine
Cheng, H., Liu, Z., Xue, H., Gout, P. W., & Shan, H. (2017) · Molecular and translational medicine · doi:10.1007/978-3-319-55825-7_12 · Cited by 3 · see citing works
Assessing Preclinical Research Models for Immunotherapy for Gynecologic Malignancies
Dholakia, J., Scalise, C. B., & Arend, R. C. (2021) · Cancers · doi:10.3390/cancers13071694 · Cited by 3 · see citing works
Chitcholtan, K., Dyer, A., & Sykes, P. H. (2023) · Clinical and Experimental Obstetrics & Gynecology · doi:10.31083/j.ceog5010212 · Cited by 2 · see citing works
Chang, Y., Wu, K., Wang, K., & Ding, D. (2023) · Cells · doi:10.3390/cells12222635 · Cited by 2 · see citing works
Patient-Derived Tumor Xenografts in Hematologic Disorders
Pizzi, M., & Inghirami, G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804010-2.00022-9 · Cited by 2 · see citing works
Studies of Cancer Heterogeneity Using PDX Models
Wen, D., Zhang, F., & Long, Y. (2017) · Molecular and translational medicine · doi:10.1007/978-3-319-55825-7_5 · Cited by 2 · see citing works
Howell, V. M., & Davidson, B. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00205 · Cited by 2 · see citing works
Patient-Derived Xenografts in Oncology
Adeegbe, D. O., & Liu, Y. (2016) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-45397-2_2 · Cited by 1 · see citing works
Are we ready to take full advantage of patient‐derived tumor xenograft models?
Kyriakides, P. W., & Inghirami, G. (2017) · Hematological Oncology · doi:10.1002/hon.2419 · Cited by 1 · see citing works
Sahashi, S., Shimada, K., Takagi, Y., Aoki, T., Kunou, S., Sakamoto, A., Murase, A., Furukawa, K., Kagaya, Y., Yamaga, Y., et al. (2023) · International Journal of Hematology · doi:10.1007/s12185-023-03604-z · Cited by 1 · see citing works
Preclinical models in ovarian cancer
Bolland, D. E., & McLean, K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814704-7.00002-7 · Cited by 1 · see citing works
Steinkamp, M. P., Lagutina, I. V., Brayer, K. J., Schultz, F. A., Burke, D., Pankratz, V. S., Adams, S. F., Hudson, L. G., Ness, S. A., & Wandinger‐Ness, A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.01.498335 · Cited by 1 · see citing works
Patient-Derived Xenograft Models of Ovarian/Gynecologic Tumors
Liang, L., Mercado‐Uribe, I., Niu, N., Jiang, Y., Cheng, W., Zhang, J., Mills, G. B., Scott, C. L., Sood, A. K., & Liu, J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804010-2.00019-9
Models of ovarian cancer to test new agents
Sodi, V. L., Craig, A. D., Peri, S., & Connolly, D. C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819840-7.00012-1
Ovarian Cancer: Towards Personalizing Ovarian Cancer Treatments Using Patient-Derived Organoids
Volpari, T., Hebner, J., Aiyar, R. S., & Martin, L. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00080-3
Modeling the Tumor Microenvironment in Patient-Derived Xenografts: Challenges and Opportunities
Kleinmanns, K., Gjerde, C. H., Langer, A., Fosse, V., de Jalón, E. G., Leitch, C., Popa, M. L., Gélébart, P., & McCormack, E. (2022) · Springer eBooks · doi:10.1007/978-3-030-98950-7_19
Engineering Approaches in Ovarian Cancer Cell Culture
Iwanicki, M., Pavlovič, T., & Behboodi, P. (2023) · Current cancer research · doi:10.1007/978-3-031-22802-5_8
Saha, N., Lee, S. G., de Stanchina, E., Mendoza, R. P., Veach, D. R., & Nikolov, D. B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27072936
Targeted Therapies: Precision in Cancer Treatment
Kumar, M., Awasthi, A., Jindal, P., & Chauhan, D. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814144126010005
- Authors
- Scott, C. L., Becker, M. A., Haluska, P., & Samimi, G.
- Affiliations
- The Royal Melbourne Hospital (AU)
- Mayo Clinic (US)
- Garvan Institute of Medical Research (AU)
- Corresponding author
- Samimi, Goli
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2013
- Volume
- 3
- Pages
- 295-295
- ISSN
- 2234-943X (ISSN-L)
- PMC
- PMC3849703
- OpenAlex
- W2125633887
- Cited by
- 100
- References
- 58
- Citations by year
- 2026: 2 · 2025: 3 · 2023: 6 · 2022: 7 · 2021: 11 · 2020: 9 · 2019: 9 · 2018: 4 · 2017: 12 · 2016: 12 · 2015: 19 · 2014: 5 · 2013: 1
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Frontiers in Oncology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ovarian Cancer Research Fund (OCRF258797)
- Australian Government
- Australian Cancer Research Foundation
- Cancer Australia
- Cure Cancer Australia Foundation
- Petre Foundation
- Medical Research Council
- National Health and Medical Research Council
- Cancer Council Victoria
- Cancer Council NSW
- National Cancer Institute (P50CA136393)
- National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007352)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- patient-derived xenografts, epithelial ovarian cancer, high-grade serous ovarian cancer, targeted therapy, predictive biomarkers, precision medicine, platinum response, tumor heterogeneity, molecular alterations, preclinical drug testing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
